Voya Investment Management LLC Has $1.61 Million Stake in Xenon Pharmaceuticals Inc. $XENE

Key Points

• Voya Investment Management LLC reduced its stake in Xenon Pharmaceuticals (NASDAQ:XENE) by 23.0%, now holding approximately 48,065 shares valued at $1.61 million.
• Other institutional investors, including Ameriprise Financial Inc. and Bank of New York Mellon Corp., increased their positions significantly, with Bank of New York Mellon boosting its stake by 439.0%.
• Xenon Pharmaceuticals reported an EPS of ($1.07) in its recent quarterly earnings, missing analysts' expectations, while analysts project a future EPS of -3.1 for the year.

Voya Investment Management LLC trimmed its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 23.0% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,065 shares of the biopharmaceutical company's stock after selling 14,350 shares during the period. Voya Investment Management LLC owned about 0.06% of Xenon Pharmaceuticals worth $1,613,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Ameriprise Financial Inc. boosted its position in shares of Xenon Pharmaceuticals by 39.1% during the fourth quarter. Ameriprise Financial Inc. now owns 92,350 shares of the biopharmaceutical company's stock worth $3,620,000 after buying an additional 25,967 shares during the period. Mutual of America Capital Management LLC acquired a new position in shares of Xenon Pharmaceuticals during the first quarter worth about $1,636,000. Natixis Advisors LLC boosted its position in shares of Xenon Pharmaceuticals by 1.9% during the first quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company's stock worth $806,000 after buying an additional 456 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Xenon Pharmaceuticals by 439.0% during the first quarter. Bank of New York Mellon Corp now owns 251,147 shares of the biopharmaceutical company's stock worth $8,426,000 after buying an additional 204,550 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ boosted its position in shares of Xenon Pharmaceuticals by 17.5% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 47,457 shares of the biopharmaceutical company's stock worth $1,592,000 after buying an additional 7,081 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $37.40 on Tuesday. The stock has a market capitalization of $2.88 billion, a PE ratio of -10.54 and a beta of 1.17. The business has a fifty day moving average price of $35.46 and a two-hundred day moving average price of $33.84. Xenon Pharmaceuticals Inc. has a fifty-two week low of $26.74 and a fifty-two week high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same period in the prior year, the business earned ($0.75) earnings per share. On average, equities analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on XENE. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 2nd. Wells Fargo & Company began coverage on Xenon Pharmaceuticals in a research report on Wednesday, September 3rd. They set an "overweight" rating and a $48.00 price objective for the company. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, August 12th. Finally, Wedbush upped their target price on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an "outperform" rating in a report on Tuesday, August 12th. Eleven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $53.30.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.